Literature DB >> 28724177

Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS.

V Cappelli1, M C Musacchio, A Bulfoni, G Morgante, V De Leo.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of women of reproductive age and a complex endocrine condition, due to its heterogeneity and uncertainty about its etiology. However, PCOS is also associated with other metabolic abnormalities such as insulin resistance, impaired glucose tolerance, and diabetes. There are few medications that are approved for the most common symptoms of PCOS, leading to the off-label use of medications that were approved for other indications. One of the most common medications being used off label for PCOS is metformin. Research of other effective therapeutic options has included the utility of inositol. PATIENTS AND METHODS: A systematic literature search of PubMed was performed using the following combination of terms: 'PCOS', 'hyperandrogenism' 'inositol', 'natural molecules'. Only papers published between 2000 and 2016 were included in our analysis. The present review analyzes all aspects of the choice of natural molecules in the treatment of hyperandrogenism and metabolic disorders in PCOS women.
RESULTS: The rationale underlying the use of inositols as a therapeutic application in PCOS derives from their activities as insulin mimetic agents and their salutary effects on metabolism and hyperandrogenism without side effects.
CONCLUSIONS: In this review will discuss the role of a number of natural associations between inositol and different substances in the treatment of hyperandrogenic symptoms in PCOS women.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28724177

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  miR-124-3p Combined with ANGPTL2 Has High Diagnostic Values for Obese and Nonobese Polycystic Ovary Syndrome.

Authors:  Hongmei Dai; Fangting Liu; Jianshu Lu; Yan Yang; Pingping Liu
Journal:  Int J Endocrinol       Date:  2022-06-14       Impact factor: 2.803

2.  Endometrial and follicular development following stair-step and traditional protocols in women with polycystic ovary syndrome: An RCT.

Authors:  Sholeh Shahgheibi; Fariba Seyedoshohadaei; Danial Khezri; Solmaz Ghasemi
Journal:  Int J Reprod Biomed       Date:  2021-07-27

3.  Cryptotanshinone Protects against PCOS-Induced Damage of Ovarian Tissue via Regulating Oxidative Stress, Mitochondrial Membrane Potential, Inflammation, and Apoptosis via Regulating Ferroptosis.

Authors:  Honglin Liu; Jiani Xie; Limin Fan; Yue Xia; Xia Peng; Jianhua Zhou; Xiaorong Ni
Journal:  Oxid Med Cell Longev       Date:  2022-04-04       Impact factor: 6.543

Review 4.  Polycystic Ovary Syndrome: A Disorder of Reproductive Age, Its Pathogenesis, and a Discussion on the Emerging Role of Herbal Remedies.

Authors:  Ling-Hui Zeng; Saba Rana; Liaqat Hussain; Muhammad Asif; Malik Hassan Mehmood; Imran Imran; Anam Younas; Amina Mahdy; Fakhria A Al-Joufi; Shaymaa Najm Abed
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

Review 5.  PCOS Physiopathology and Vitamin D Deficiency: Biological Insights and Perspectives for Treatment.

Authors:  Giuseppe Morgante; Ilenia Darino; Amelia Spanò; Stefano Luisi; Alice Luddi; Paola Piomboni; Laura Governini; Vincenzo De Leo
Journal:  J Clin Med       Date:  2022-08-02       Impact factor: 4.964

6.  Serum Levels of Angiopoietin-Like Protein 2 and Obestatin in Iranian Women with Polycystic Ovary Syndrome and Normal Body Mass Index.

Authors:  Elham Rahmani; Samad Akbarzadeh; Ainaz Broomand; Fatemeh Torabi; Niloofar Motamed; Marzieh Zohrabi
Journal:  J Clin Med       Date:  2018-06-22       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.